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nanoparticles upon deposition at the human
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Background: Plasmid DNA vaccination is a promising approach, but studies in non-human primates and humans
failed to achieve protective immunity. To optimise this technology further with focus on pulmonary administration,
we developed and evaluated an adjuvant-equipped DNA carrier system based on the biopolymer chitosan. In more
detail, the uptake and accompanying immune response of adjuvant Pam3Cys (Toll-like receptor-1/2 agonist)
decorated chitosan DNA nanoparticles (NP) were explored by using a three-dimensional (3D) cell culture model of
the human epithelial barrier. Pam3Cys functionalised and non-functionalised chitosan DNA NP were sprayed by a
microsprayer onto the surface of 3D cell cultures and uptake of NP by epithelial and immune cells (blood
monocyte-derived dendritic cells (MDDC) and macrophages (MDM)) was visualised by confocal laser scanning
microscopy. In addition, immune activation by TLR pathway was monitored by analysis of interleukin-8 and tumor
necrosis factor-α secretions (ELISA).
Results: At first, a high uptake rate into antigen-presenting cells (MDDC: 16-17%; MDM: 68–75%) was obtained.
Although no significant difference in uptake patterns was observed for Pam3Cys adjuvant functionalised and
non-functionalised DNA NP, ELISA of interleukin-8 and tumor necrosis factor-α demonstrated clearly that Pam3Cys
functionalisation elicited an overall higher immune response with the ranking of Pam3Cys chitosan DNA NP >
chitosan DNA NP = DNA unloaded chitosan NP > control (culture medium).
Conclusions: Chitosan-based DNA delivery enables uptake into abluminal MDDC, which are the most immune
competent cells in the human lung for the induction of antigen-specific immunity. In addition, Pam3Cys adjuvant
functionalisation of chitosan DNA NP enhances significantly an environment favoring recruitment of immune cells
together with a Th1 associated (cellular) immune response due to elevated IL-8 and TNF-α levels. The latter renders
this DNA delivery approach attractive for potential DNA vaccination against intracellular pathogens in the lung
(e.g., Mycobacterium tuberculosis or influenza virus).
Keywords: Triple cell co-culture, Dendritic cells, Macrophages, Bronchial epithelium, Toll-like receptor agonist,
Adjuvant, Chitosan DNA nanoparticlesBackground
In general, plasmid DNA (pDNA) vaccines consist of a
bacterial plasmid vector, which contains the genetic infor-
mation encoding for a single- or multi-epitope antigenic
protein. pDNA vaccines are usually produced in bacteria
(e.g., Escherichia coli), purified and injected into the host
[1]. When compared to gene therapy, vaccination using* Correspondence: Gerrit.Borchard@unige.ch
1School of Pharmaceutical Sciences Geneva-Lausanne (EPGL), University of
Geneva, University of Lausanne, Geneva, Switzerland
Full list of author information is available at the end of the article
© 2013 Heuking et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpDNA is thought to be effective already at relatively low
levels of gene expression. Promising results of pDNA im-
munisation were obtained in preclinical settings [2], how-
ever, studies in non-human primates and humans failed to
achieve protective immunity [3-5]. Consequently, amelior-
ation strategies of pDNA vaccination were exploited,
ranging from plasmid optimisation, co-formulation with
adjuvants to changing to a specific route of administration,
e.g., pulmonary vaccination.
Nebulisation of vaccines is regarded as a promising
route of immunisation [6] owing to several clinical trialsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phase II/III [9]. It is generally assumed that mimicking
the natural way of infection by applying vaccines to the
respiratory tract represents an auspicious strategy for
the prevention of lung infections (e.g., influenza, measles
and tuberculosis).
Further advantages are:
i) delivery of vaccines into the respiratory tract elicits
the secretion of local antibodies (IgA), which in turn
are capable of crossing epithelia and preventing
further entrance of pathogens [10];
ii) the particular non-invasive nature of pulmonary
antigen delivery circumvents the common use of
needles, which is the major cause for unsafe
injections especially in developing countries [11];
iii) use of pulmonary dry powder vaccines may
circumvent the common imperative of an intact
cold chain for vaccine storage [9];
iv) trained medical personnel may not be required for
the administration of vaccines by inhalers.
Next to these benefits, aerosol delivery of pDNA vac-
cines using poly(ethyleneimine) or polymeric chitosan
NP elicited in mice superior antigen-specific immune
responses compared to intramuscular injection [12-14].
Furthermore, pulmonary DNA vaccination against the
vaccinia virus induced immunity also at different
mucosal effector sites (gut, vagina) and protected against
subsequent virus challenge, whereas intramuscular im-
munisation did not [14]. Above mentioned studies on
pulmonary DNA vaccination used the PennCentury™
microsprayer, which was shown to deliver micrometer
sized droplets into the bronchial tract (bronchi and
bronchioles) of mice [15]. In addition, the bronchial
tract is considered expedient for vaccination purposes
due to less local mucociliary clearance in comparison to
the upper airways, which gives rise to increased particle
retention times from <24 h to several days [16].
In order to investigate the fate of deposited particles
and resulting immune responses within the human
bronchial tract, a three-dimensional (3D) cell model of
the human bronchial epithelial airway barrier was shown
to be a versatile tool next to animal and ex vivo systems
[17,18]. This 3D cell culture model is composed of a
monolayer of human bronchial epithelial cells, with the
addition of immune cells: human monocyte-derived
macrophages (MDM) on the top and of blood mono-
cyte-derived dendritic cells (MDDC) underneath of the
epithelial cell monolayer. Generally, MDM and MDDC
belong to the group of antigen-presenting cells (APC)
together with B lymphocytes. Uptake of antigens into
APC represents the very first and mandatory step to-
wards the induction of an antigen-specific immunity.Among all APC dendritic cells (DC) are the most com-
petent immune cells and have to be targeted by the
antigen or an in situ antigen-producing system (DNA
vaccine) for successful antigen-specific immunisation.
In addition to pulmonary (bronchial) DNA vaccin-
ation, another strategy to improve the immunogenicity
of DNA vaccines is to include highly purified synthetic
adjuvants, which are able to activate distinct parts of the
immune system. For effective vaccination, the adjuvant
should be co-formulated with the antigen within the
same delivery vector [19]. Therefore, a final formulation
contains 1) the antigen, 2) the adjuvant, stimulating
strongly the innate immune system and 3) a particulate
delivery system assuring optimal presentation of 1 and 2
to the immune system (especially DC) [19].
In order to address these necessities, we recently
synthesised a novel co-polymer, CTPPC, based on poly-
meric chitosan, as a delivery system [20]. To a new
chitosan derivative, 6-0-carboxymethyl-N,N,N-trimethyl-
chitosan (CTC), a Pam3Cys moiety, an adjuvant activating
the innate immune system, was grafted through a poly
(ethylene glycol) (PEG) spacer (final co-polymer abbrevi-
ated CTPPC). Of note, the Pam3Cys molecule has a
triacylated moiety and belongs to the group of TLR-1
/TLR-2 heterodimer agonists whereas the TLR-2 can also
form dimers with TLR-6 when activated with diacylated
based agonists (such as Pam2Cys). In a second step,
Pam3Cys functionalised nanoparticles (NP) were prepared
by complex coacervation of CTPPC with pDNA express-
ing the green fluorescence protein (GFP) [21]. With regard
to the adjuvanticity of the new delivery system, we ob-
served that Pam3Cys functionalised pGFP NP induced
Interleukin-8 (IL-8) secretion from differentiated THP-1
human macrophages, which was increased by 10-fold
compared to non-functionalised carriers [21]. Moreover,
both innate immune receptors TLR-1 and TLR-2 are
highly expressed in the pulmonary macrophages, dendritic
and epithelial cells [22,23]. Consequently, we considered
the CTPPC NP system for pulmonary (bronchial) DNA
vaccination and studied its adjuvanticity using a well-
established 3D cell model of the human bronchial epithe-
lial airway barrier. In our study, we aerosolised DNA
loaded NP by the PennCenturyTM microsprayer onto this
3D cell culture model and examined the uptake of NP by
epithelial and immune cells (MDDC and MDM). In
addition, we quantified changes in immune response due
to NP exposure by measuring the secretions of relevant
cytokines, IL-8 and TNF-α.
Results and discussion
Chitosan-based DNA NP enter MDM, MDDC and epithelial
cells
In order to achieve protective immunity against a de-
sired antigen, the antigen has to reach DC as the most
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DC have maintained during their evolution many of
so-called pattern recognition receptors (PRR) and thus
possess the ability of sensing invasion of bacterial and
viral pathogens [24,25]. After encounter of such anti-
gens, immature DC become activated, initiate antigen
internalisation and transform into a mature state with
high T cell stimulating capability. Thereafter, mature DC
migrate to local draining lymph nodes and present the
antigen to resident T cells [26]. After successful antigen
presentation, naïve T cells become activated, migrate
back to the site of antigen exposure within the lung and
eliminate infected cells.
In that interplay, pulmonary DC were shown to play a
crucial role in lung defense [27,28] and to be imperative
for the maintenance of T cell activity as well as for a
constant stimulation of T cells, even after their migration
to infected lung tissues [29].
However, in view of pulmonary vaccination, human
DC are difficult to study, because they are sparse and
make up only a small percentage of the pulmonary cell
population [30]. In order to investigate the uptake of
particulate matter into pulmonary or more precisely
bronchial DC, as well as to follow their interplay with
macrophages and bronchial epithelial cells in vitro, a 3D
cell culture model was developed over recent years
consisting of bronchial epithelial cells combined with
MDM and MDDC [17]. In our study, three different cat-
egories of chitosan-based pDNA NP were included for
exposition onto this 3D cell culture: 1) empty CTC NP,
2) pGFP-loaded CTC NP and 3) pGFP-loaded CTPPC
NP. This experimental design allowed studying the influ-
ence of pGFP and TLR-1/2 agonist components. At first,
NP were analysed for their physico-chemical properties
(Table 1). Similar properties were already reported in
our previous publication [31]. It has to be mentioned
that these pGFP formulations had a somewhat polydis-
perse size distribution (PDI around 0.3), which was
already noticed for other chitosan pDNA formulations
[31,32]. Reducing PDI of CTC and CTPPC pDNA NP
could be achieved in the future using additional
agents like poly-γ-glutamic acid [32] or pentasodium
tripolyphosphate [33]. For the administration of NPTable 1 Characteristics of chitosan derivatives: molecular wei
potential (ZP), polydispersity index (PDI) and loading efficien
study
Formulation MW Size
(g/mol) (nm)a
CTC NP 98,330 232.9 ± 16.1
pGFP-loaded CTC NP 98,330 304.1 ± 13.0
pGFP-loaded CTPPC NP 259,000 327.3 ± 16.2
aanalyses were performed in triplicates; n/a, not applicable.suspensions, we sprayed these onto described cells (at an
air-liquid interface) by using the PennCentury™ micro-
sprayer device, which is commonly used for intratracheal
administration in mice [15]. This microsprayer creates a
fine plume of aerosolised liquid and gives therefore a
more realistic way of NP administration than the simple
addition of NP suspensions into the corresponding cell
culture medium. After exposure for 24 h, cells were
fixed and stained for F-actin in addition to the labelling
of specific surface markers, CD14 for MDM, and CD86
for MDDC.
Regarding the overall assessment of NP internalisation
into the particular cell types, we were able to assess the
percentage of internalised NP with the help of XY- and
XZ-projections. As a result, we found that MDM (at the
apical side of epithelial cells) phagocytosed the majority
of NP applied (68 – 75%). MDDC located at the
basolateral side were found to have internalised 16 –
17% of NP, and epithelial cells (EC) ingested a minor
percentage of NP of 8 – 15% (see Figure 1). Moreover,
the extent of NP uptake was irrespective of pGFP-
loading or Pam3Cys functionalisation. In previous inves-
tigations involving virosomes (0.1 - 0.2 μm in size) and
polystyrene particles (0.2 μm and 1.0 μm in size), similar
uptake patterns with MDDM >MDDC > epithelial cells
were observed [18,28,34]. Regarding the uptake, it can
be deduced that the use of chitosan-based NP facilitated
mainly (> 85%) transport of the plasmid pGFP into APC
(MDM, MDDC), whereas pGFP alone is expected to be
degraded upon deposition via extra- and intracellular
DNases [35]. In our laboratory, we remarked that the
application of pGFP alone did not result in GFP expres-
sion in alveolar A549 and bronchial HBE cells, whereas
the co-polymer CTPPC mediated GFP transfection in
both cell lines as evidenced by fluorescence microscopy
(unpublished observations).
In general, complexation with positively charged poly-
mers shields pDNA from enzymatic degradation by
endo- and exonucleases through the formation of poly-
electrolyte complexes (PEC). In previous studies we
found that complexation with the chitosan polymer
protected the plasmid pGFP against the enzyme DNase
I, which was in contrast to the complete degradation ofght (MW) and NP: z averaged particle size (Size), ζ
cy (LE) of chitosan-based DNA preparations used in this
ZP PDIa LE
(mV)a (%)a
21.3 ± 1.2 0.248 ± 0.038 n/a
17.5 ± 1.6 0.342 ± 0.041 92.5 ± 2.5
15.8 ± 1.6 0.366 ± 0.053 89.4 ± 3.8
Figure 1 Uptake of pGFP NP into MDM, MDDC or epithelial
cells (EC): unloaded CTC NP (white square), CTC pGFP NP
(black shaded white square) and CTPPC pGFP NP (black dotted
white square). Presented data are the mean ± standard error of the
mean of three independent experiments. Differences were conside-
red significant for * (p < 0.05).
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Although pGFP alone was not studied as a control in this
3D cell culture system, it appears that the use of CTC and
CTPPC for pDNA delivery is favourable due to protection
against enzymatic degradation as mentioned above, and
most likely higher uptake rates into APC in vitro.
Considering different functions of each cell type in this
triple in vitro model, MDM constitute the first line of
defence and are constantly exposed to the entry of anti-
genic materials into the human lung. MDM also have
the ability to inhibit virus growth and to eliminate
infected cells. Moreover, activated macrophages can
produce antiviral factors (e.g., TNF-α or IFN-α/β) and
chemokines (e.g., IL-8), which are able to activate
additional cell types in the fight against infections [36].
Although MDM possess only a minor antigen-presen-
ting capacity, a direct cross-talk by exchanging NP with
MDDC was proposed [24,37].
In line with our study, CLSM images of human CD14-
positive MDM demonstrated that a pronounced phagocyt-
osis of NP took place (arrow, Figure 2). XY- andFigure 2 CLSM micrographs of phagocytosed NP (green) by MDM (bl
indicates the optical section of the YZ projections (right image) and the gr
clearly indicate that NP are mainly taken up by MDM (arrow). Extracellular NXZ-projections also allowed for the recognition of non-
phagocytosed NP for comparative purposes (encircled,
Figure 2). Furthermore, we reconstructed the apical part
of the triple cell co-culture by imaging software, where NP
internalisation was detected in all three experimental
groups (Figure 3, arrow). Besides, considering the import-
ant function of DC as APC, we investigated the capturing
of NP by MDDC (located within and beneath the epithe-
lium). It was suggested that MDDC extend pseudopodia
even in the absence of apical particles through the epithe-
lium towards the luminal side [38]. Once particles are de-
posited, MDDC can rapidly induce internalisation (within
minutes) followed by transport to the apical side of the
epithelium [38]. In our study, we observed uptake of
chitosan-based NP into MDDC after 24 h by CLSM
(Figure 4). In addition, software reconstructions of the
basal part of the 3D cell co-culture model were performed
(Figure 5) and corroborated that finding. From these
visualisations it becomes clear that MDDC were capable
of taking up all three categories of chitosan-based NP.
Considering the uptake mechanism of particulate mat-
ter, Blank et al. [38] proposed different ways of particle
transport through the epithelium by MDDC: i) uptake of
particles through cellular extensions of MDDC across
the epithelium, ii) crossing of MDDC through the entire
epithelium followed by particle uptake, iii) particle
exchange between MDDC, iv) transfer of particles from
MDM to MDDC via cell–cell contacts and v) transfer of
particles through interactions of MDM with MDDC
located within or at the basolateral side of the epithe-
lium. Although we were not able to reveal the exact
way of MDDC migration towards NP followed by NP
uptake, we found a certain percentage of NP (16-17%)
internalised by MDDC after 24 h of exposure. It is
highly possible that during the exposure to NP, MDDC,
but also MDM, were stimulated by deposited chitosan-
based NP. We therefore analyzed for the secretion of
two relevant immune mediators, IL-8 and TNF-α.ue). The pictures represent single optical sections; the red line
een line the XZ projections (upper image). XY and XZ-projections
P are encircled. The horizontal bar represents 20 μm.
Figure 3 Visualisation of NP uptake in the apical part of the
triple cell culture model (actin, white; macrophages, blue;
nanoparticles, green). The pictures represent 3D renderings of the
complete data set and the actin as well as the macrophage labeling
was made transparent to show intracellular nanoparticles. A) unloa-
ded CTC NP, B) CTC pGFP NP and C) CTPPC pGFP NP. Arrows
indicate internalised NP into MDM; extracellular NP are encircled.
White bar represents a 20 μm scale.
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augments the immune response
In order to investigate a potentially higher adjuvanticity
of CTPPC pGFP NP due to the adjuvant functionalisa-
tion (TLR-1/2 agonist Pam3Cys), we studied the expres-
sion of two representative cytokines, IL-8 and TNF-α, in
the basal compartment of the triple cell co-culture sys-
tem. With regard to the first cytokine, IL-8 has a role as
an essential regulator for the recruitment of leukocytes
and their successive trafficking to the mucosal site ofinfection (chemotaxis). In terms of vaccination, signifi-
cantly higher levels of IL-8 from human macrophages
and monocytes were correlated to a higher adjuvanticity
in vitro and in vivo [38], which was explained by the
finding that for particulate adjuvants local recruitment
of innate immune cells manifests a critical step. Two li-
censed adjuvants in Europe, aluminum salts and MF59™,
are known to induce IL-8 from human macrophages
in vitro, which was brought into correlation with mouse
in vivo data [39].
In our study, we remarked that unloaded CTC NP had
a weak ability to trigger IL-8 expressions (8.7 ± 1.1 ng/
mL), although the difference was not significant (p >
0.05) in comparison to control (Figure 6). An IL-8 indu-
cing property of polymeric chitosan was already indi-
cated by Park et al. and might be caused (at least in
parts) by complement activation [40]. Secondly, we ob-
served a significant (p < 0.05) higher release of IL-8
owing to Pam3Cys functionalisation of pGFP NP (CTC
NP: 9.2 ± 0.4 ng/mL; CTPPC NP 13.7 ± 0.8 ng/mL).
Spohn et al. [41] and Sadik et al. [42] already described
the IL-8 eliciting capacity of Pam3Cys on stably TLR-2
transfected HEK cells and differentiated THP-1 macro-
phages, respectively. The general trend of these IL-8 re-
sults goes in line with our previous report [21], in which
we noted a 10-fold higher induction of IL-8 from differ-
entiated human-like macrophages (THP-1) by virtue of
Pam3Cys functionalisation. Next to the chemokine IL-8
and in order to assess the quality of immune responses,
we analysed for TNF-α secretions from the 3D cell cul-
ture system. TNF-α is an important pro-inflammatory
cytokine in host defense and is produced from a variety
of immune cells, such as macrophages, T lymphocytes
and dendritic cells. TNF-α is associated with a bias to-
wards a T helper cell type 1 (Th1) immune response
favouring the induction of cellular immunity. Major
functions of TNF-α are recruitment of inflammatory
cells, cell differentiation and subsequent elimination of
intracellular pathogens. Generally, it appears that the
expression levels of TNF-α need to be well balanced. On
one side, complete blocking of TNF-α with anti-TNF-α
antibodies (as treatment for rheumatoid arthritis) was
correlated to increased risks of tuberculosis, viral infec-
tions and even reactivated latent infections of tubercu-
losis in several patients [42]. On the other hand, TNF-α
overproduction can cause tissue damage, impair DC
development and even septic shock [43]. Of note, the
exposure of immature DCs to an aluminum adjuvant
and MF59™ did not result in secretion of TNF-α,
whereas LPS as TLR-4 agonist elicited significant levels
of expression [44].
In our study, we found significant secretions of TNF-α
being ranked by CTPPC pGFP NP >CTC pGFP NP =
unloaded CTC NP >medium control (Figure 7). We
Figure 4 CLSM micrographs of phagocytosed NP (green) by MDDC (blue). The pictures represent single optical sections; the red line
indicates the optical section of the YZ projections (right image) and the green line the XZ projections (upper image). XY and XZ-projections
clearly indicate that NP are internalised by MDDC (arrow). Extracellular NP are encircled. Horizontal bar represents 20 μm.
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of TNF-α in comparison to control (not significant).
Related to that, Otterlei et al. [45] demonstrated that
chitosan (depending on its molecular weight and degree
of deacetylation) can induce TNF-α production from
human monocytes in a CD14-dependent manner. Inter-
estingly, the additional functionalisation with Pam3Cys
increased significantly (p < 0.05) TNF-α secretion (2.3 ±
0.2 ng/mL), when compared to unmodified CTC pGFP
NP (1.6 ± 0.2 ng/mL; Figure 7). Schjetne et al. [46]
reported that the Pam3Cys moiety stimulates CD14-
positive human monocytes as well as immature DC via
TLR-2 pathway to produce rather high levels of TNF-α
(around 1.5 – 2.0 ng/mL), which were in a similar range
as those induced by bacterial LPS (as their control) and
by CTTPC pGFP NP in our study. In addition, more
recent immunisation studies in mice support that the
distinct Pam3Cys moiety stimulates TNF-α expressions
in lung tissues [47] and DCs [48].
Conclusions
The uptake of chitosan-based DNA NP by immune com-
petent MDDC being located at the abluminal side of the
human 3D cell culture was demonstrated by using CLSM.
ELISA of IL-8 and TNF-α demonstrated clearly that
Pam3Cys (TLR-1/2 agonist) functionalisation facilitates an
overall higher immune response with the ranking of
CTPPC pGFP NP >CTC pGFP NP = unloaded CTC NP >
medium control. It can be concluded that novel CTPPC
NP has interesting adjuvant properties due to i) protection
against enzymatic degradation; ii) transfection in vitro; iii)
transport of DNA into the most immune competent APC
type, namely DC and iv) increasing the overall immune
response (IL-8, TNF-α) being favorable for pulmonary
DNA against intracellular pathogens. Currently studies are
ongoing in wild type and knockout mice to confirm the
potential of the NP systems described here to elicit an
immune response on mucosal application.Methods
Triple cell culture
The triple cell culture system was established as previ-
ously published [17,38]. Briefly, bronchial 16HBE14o-
cells (passage numbers 2.45–2.80) were maintained in
MEM 1×, with Earle’s Salts, 25 mM HEPES, without
L-Glutamine (Gibco BRL, Switzerland) supplemented with
1% L-Glutamine (LabForce AG, Switzerland), 1% penicil-
lin/streptomycin (Gibco BRL, Switzerland), and 10%
fetal calf serum (PAA Laboratories, Lucerna-Chem AG,
Switzerland) on transparent BD Falcon cell culture inserts
(pores with 3.0 μm diameter, PET membranes for 6-well
plates; BD Biosciences, Switzerland) treated with fibronec-
tin coating solution containing bovine serum albumin,
0.1 mg/ml (Sigma, Fluka Chemie GmbH, Switzerland)
with 1% bovine collagen, Type I (BD Biosciences,
Switzerland) and 1% human fibronectin (BD Biosciences,
Switzerland) in LHC Basal Medium (Lucerna Chemie AG,
Switzerland). The cells were grown for 7 days.
MDM and MDDC were derived from human blood
monocytes as previously described [17]. Briefly, peripheral
blood monocytes were isolated from buffy coats (Blood
Donation Service, Bern, Switzerland) and cultured in the
same medium as used for the epithelial cells except for the
supplementation of 5% human serum (Blood Donation
Service, Bern, Switzerland) instead of 10% fetal calf serum.
Regarding the generation of MDDC, monocytes were cul-
tured for 7 days in medium supplemented with 34 ng/ml
of IL-4 (Sigma, Fluka Chemie GmbH, Switzerland) and
with 50 ng/ml of GM-CSF (R&D Systems, Oxon, UK),
whereas MDM were obtained without any additional sup-
plements. After 7 days in mono-cultures MDM were
added at the apical and MDDC at the basolateral side of
the epithelial monolayer as described in detail by Rothen-
Rutishauser et al. [17].
Next, the triple cell co-cultures were kept overnight
in medium supplemented with 1% L-glutamine, 1%
penicillin/streptomycin, and 5% heat-inactivated (pooled)
Figure 5 Visualisation of different NP in the basal compartment
of triple cell culture model (actin, white; dendritic cells, blue;
nanoparticles, green). The pictures represent 3D renderings of the
complete data set and the actin as well as the dendritic cell labeling
was made transparent to show intracellular nanoparticles. A)
unloaded CTC NP, B) CTC pGFP NP and C) CTPPC pGFP NP. Arrow
marks internalised NP into MDDC; extracellular NP are encircled.
White bar represents a 20 μm scale.
Figure 6 IL-8 release into the basolateral compartment from
triple co-culture cell model due to exposure to unloaded CTC
NP, CTC pGFP NP and CTPPC pGFP NP. Presented data are the
mean ± standard error of the mean of three independent experi-
ments. Differences were considered significant for * (p < 0.05) in
comparison to cells treated with culture medium unless indicated
otherwise; NS, not significant.
Figure 7 TNF-α release into the basolateral compartment from
triple co-culture cell model due to exposure of unloaded CTC
NP, CTC pGFP NP and CTPPC pGFP NP. Presented data are mean
± standard error of the mean of three independent experiments.
Differences were considered significant for * (p < 0.05) in comparison
to cells treated with culture medium unless indicated otherwise;
NS, not significant.
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5% CO2 humidified atmosphere. The following day the
medium was removed completely from the apical cham-
ber while 1.2 mL of medium was kept in the basolateral
well to feed the cultures from the basal side of the insert.The cells were exposed to air for 24 h at 37°C in a 5%
CO2 humidified atmosphere as described earlier [38].
NP preparation and characterization
Synthesis of CTC with a degree of carboxymethylation
of 23.2% and degree of trimethylation of 33% and subse-
quent synthesis of CTPPC with a degree of grafting of
about 2.1% was performed as described earlier based on
an endotoxin-free polymeric chitosan (KitoZyme S.A.,
Herstal, Belgium) [21]. In addition to our previous publi-
cation, we analysed the molecular weight of chitosan
derivatives by SEC-MALLS. Hereby, measurements were
performed using a TOSOH TSK Gel G3000PWXL-CP
size exclusion column (TOSOH Bioscience, Germany)
with 0.2 M sodium acetate/0.3 M acetic acid (pH 4.4) as
eluent (0.3 mL/min). A Waters Alliance HPLC system
coupled to a differential refractive index (RI) detector
(Schambeck, Germany) and a light scattering detector
(MiniDawn, Wyatt, USA) was used for sample handling.
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g/mol (PSS, Germany) were used for calibration. Next,
in order to fluorescently label NP, we selected an Alexa
Fluor 488 sulfodichlorophenol dye (A30052, Invitrogen,
France). The Alexa Fluor 488 dye was coupled to free
amine moieties of CTC and CTPPC (at 1% molar ratio of
sugar units), respectively, according to manufacturer’s
recommendation. Emission spectra (excitation at λ =
495 nm) of labeled chitosan derivative were taken using a
FluoroMax spectrometer (Spex, Switzerland) and no
quenching was observed. Successively, NP were formed
according to our published method [21]. Briefly, CTPPC
(at 3.10 mg/mL, average molecular weight per sugar unit
of 290.8 Da, 3.6 μmol/mL -N+(CH3)3, N) or CTC (at
2.21 mg/mL, average molecular weight per sugar unit of
207.1 Da, 3.6 μmol/mL -N+(CH3)3, N) were dissolved in
Miniversol water. Separately, the endotoxin-free plasmid
pIRES-hrGFP II (abbreviated pGFP; 1 μg of pGFP being
equal to 3.1 nmol of phosphate groups, P) was dissolved in
5 mM aqueous sodium sulfate solution at a concentration
of 390 μg/mL in order to yield N/P ratios of 3:1. Both solu-
tions were heated for 5 minutes at 55°C. In the following,
the polymer containing solution was slowly added (ap-
proximately 1 drop per second) to the pGFP solution and
vortexed at low speed for 30 seconds. Attention was paid
to keep the final volume below or at 400 μL in order to ob-
tain a narrow particle size distribution. Moreover, unloaded
CTC nanoparticles (control group) were prepared with the
help of the cross-linking agent pentasodium tripolypho-
sphate (TPP) at a molar ratio of 3:1 (positive amines
N + (CH3)3 to TPP molecules) at room temperature via
dropwise addition of TPP solution (0.58 mg/mL) to slowly
vortexed polymer solution. The final volume was similarly
kept at ≤ 400 μL. All particle formulations were kept at
room temperature for at least one hour prior to further
use. After preparation, hydrodynamic diameters of labelled
NP were measured by Photon Correlation Spectroscopy
(ZetaSizer 3000 HS, Malvern, Switzerland). For each set of
measurements, 400 μL of nanoparticle suspensions were
diluted in PBS (pH 7.4) to a total of 1.4 mL. Size distribu-
tion data were obtained by the z averaged value of three
independent groups of ten measurements. In addition, the
zeta potential was measured at least in triplicate via micro-
electrophoresis by using an aqueous dip cell (ZetaSizer
3000 HS, Malvern, Switzerland). The loading efficiency of
NP was determined by centrifugation of 400 μL of nano-
particle suspension at 16,000 × g for 30 min (Centrifuge
5417C/R, Eppendorf, Germany) and quantification of the
unloaded pGFP in the supernatant by PicoGreen assay
(Quant-iT PicoGreen, Invitrogen, France) according to the
manufacturer’s specifications. Fluorescence was measured
with a FluoroMax spectrometer (Spex, Switzerland) at
excitation and emission wavelengths of 480 and 522 nm,
respectively.NP exposure on cell surface
Cytotoxicity for both polymer (IC50 > 10 μg/mL) and NP
(IC50 > 500 μg/mL) had been determined previously in
mTHP-1 cells (differentiated monocyte cell line) [21].
Particle concentrations in this study were kept well
below cytotoxic concentrations. For exposure, NP sus-
pensions (unloaded CTC NP, CTC pGFP NP and CTPPC
pGFP NP, respectively) were extemporaneously prepared
before each experiment and were diluted 1:4 in plain cell
culture medium in order to yield 4 μg of pGFP in
150 μL medium. After cultivation of cell cultures at the
air-liquid interface for 24 h, for each exposure, the re-
spective insert was taken out and placed shortly into an-
other 6-well plate (filled with 1.2 mL of full medium).
The diluted NP suspensions (150 μL per 6-well plate)
were then sprayed on the apical surface of the triple cell
co-culture using a MicroSprayer (model IA-1C, 10" long
0.64-mm tube, PennCentury™, USA). After exposure, the
insert was placed back into its original position within
the 6-well plate, incubated for another 24 h and then
fixed for microscopic analysis. Control experiments were
performed with plain cell culture medium. A total of
three independent experiments were performed.
Cell labeling and CLSM
Triple cell co-cultures were fixed and stained after NP
exposure and post-incubation as previously reported
[17]. Antibodies were diluted in PBS as follows: mouse
anti-human CD14 1:20 (Clone UCHM-1, C 7673,
Sigma, Switzerland), mouse anti-human CD86 1:20
(Clone HB15e, 36931A, PharMingen, BD Biosciences,
Switzerland), goat anti-mouse cyanine 5 1:50 (AP124S,
Chemicon, Switzerland), DAPI at 1 μg/mL (Molecular
Probes, Switzerland) and rhodamine phalloidin 1:50
(R-415; Molecular Probes, Switzerland). A Zeiss LSM
510 Meta with an inverted Zeiss microscope (Axiovert
200 M, lasers: HeNe 633 nm, HeNe 543 nm, and
Ar 488 nm, Diode laser 405 nm; Carl Zeiss AG,
Switzerland) was used. Uptake of Alexa488-labeled parti-
cles was quantified by using Zeiss LSM Image Examiner
(Carl Zeiss AG, Switzerland) on a stack per stack basis
[38]. Image processing and visualisation was performed
using IMARIS (Bitplane AG, Switzerland), a three-
dimensional multi-channel image processing software
for CLSM images. For figural representation, LSM and
reconstructed images originated from one data set of
one randomly selected experiment (out of three inde-
pendent experiments).
ELISA of IL-8 and TNF-α
Following 24 h of particle incubation, the cell culture
media of the basal chamber of triple cell co-cultures were
collected separately and stored at −80°C until further use.
After centrifugation, the cytokine tumor necrosis factor-α
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tions were quantified by a DuoSet ELISA Development kit
(DY 210 and DY 208, R&D Systems, UK) according to the
manufacturer’s recommendations, except as noted below.
The assay was performed in triplicates. An aliquot of
100 μl of the diluted capture antibody (mouse anti-human
TNF-α or IL-8, concentration of 4 μg/ml PBS) was incu-
bated overnight in a 96-well immunoassay plate (NUNC,
MaxiSorp, Switzerland) at room temperature. Differing
from the producer’s protocol, the plate was blocked with
PBS supplemented with 1% bovine serum albumin (BSA)
and 0.05% NaN3 for 1 h at room temperature. After wash-
ing with buffer, supernatants from samples and the stan-
dards (0–10 ng/mL of recombinant human TNF-α and
0–2 ng/mL of recombinant human IL-8) were pipetted
into the wells and incubated at room temperature for 2 h.
After washing, the detection antibody (biotinylated goat
anti-human TNF-α or IL-8, respectively) diluted in re-
agent diluent was added.
The plate was covered with an adhesive strip and incu-
bated again for 2 h. After washing horseradish peroxidase-
conjugated streptavidin was added to the plates and
incubated for 20 min at room temperature in the dark.
Finally, the substrate solution (tetramethylbenzidine/
H2O2; DY 999, R&D Systems, UK) was added. After
20 min in darkness, the color development was stopped
by adding 50 μL of 1 M H2SO4 and the plate was put on a
shaker (differing from the protocol) for 2 minutes. The ab-
sorbance was then read at 450 nm using an ELISA reader
(Benchmark Plus Microplate Spectrometer, Switzerland).
The concentration of the cytokine was determined by
comparing the absorbance of the samples with standard
samples using log log regressions.Statistics
Data from particle uptake quantifications and ELISA ex-
periments were expressed as the mean ± standard error
of the mean and were compared by one-way ANOVA
using Origin 7.01 software. Differences were considered
significant * at p < 0.05.
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